First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
Hematological Oncology · 2025
DOI: 10.1002/hon.70073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematological Oncology, 2025. Verfasst von E Silkenstedt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, LMU Hospital, Munich, Germany. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Agammaglobulinaemia Tyrosine Kinase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The development and implementation of new targeted and immunotherapeutic approaches in the treatment landscape of mantle cell lymphoma have already improved therapeutic options especially for refractory or relapsed disease. Regarding first‐line therapy, treatment strategies including novel agents are under investigation. In transplant‐eligible patients, a combined ibrutinib‐containing immunochemotherapy induction followed by ASCT was shown to be superior compared to the chemotherapy regimen +/− ASCT. Thus, we consider the addition of ibrutinib to first‐line therapy in younger MCL patients a new standard of care. For the group of older MCL patients ineligible for high‐dose therapy and ASCT, several targeted therapy approaches have been investigated in different studies in combination with immunochemotherapies or as single agents +/− other targeted therapies with promising results. This review summarizes the current standard of care for first‐line treatment of mantle cell lymphoma, highlighting the implementation of targeted treatment strategies, especially BTKi, in initial treatment strategies. Trial Registration: ClinicalTrials.gov identifier: NCT06482684
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine III, LMU Hospital, Munich, Germany.
Zitieren
APA
Silkenstedt, E., & Dreyling, M. (2025). First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients. Hematological Oncology. https://doi.org/10.1002/hon.70073
Vancouver
Silkenstedt E, Dreyling M. First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients. Hematological Oncology. 2025. doi:10.1002/hon.70073
BibTeX
@article{Silkenstedt2025,
author = {Silkenstedt, E and Dreyling, M},
title = {First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70073}
}
EUVIMED